Back to Search Start Over

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Authors :
Lok A
Descamps G
Tessoulin B
Chiron D
Eveillard M
Godon C
Le Bris Y
Vabret A
Bellanger C
Maillet L
Barillé-Nion S
Gregoire M
Fonteneau JF
Le Gouill S
Moreau P
Tangy F
Amiot M
Moreau-Aubry A
Pellat-Deceunynck C
Source :
Blood advances [Blood Adv] 2018 Dec 11; Vol. 2 (23), pp. 3492-3505.
Publication Year :
2018

Abstract

In this study, we assessed the sensitivity of myeloma cells to the oncolytic measles virus (MV) in relation to p53 using 37 cell lines and 23 primary samples. We showed that infection and cell death were correlated with CD46 expression, which was associated with TP53 status; TP53 <superscript> abn </superscript> cell lines highly expressed CD46 and were preferentially infected by MV when compared with the TP53 <superscript> wt </superscript> cell lines ( P = .046 and P = .045, respectively). Infection of myeloma cells was fully dependent on CD46 expression in both cell lines and primary cells. In the TP53 <superscript>wt</superscript> cell lines, but not the TP53 <superscript> abn </superscript> cell lines, activation of the p53 pathway with nutlin3a inhibited both CD46 expression and MV infection, while TP53 silencing reciprocally increased CD46 expression and MV infection. We showed using a p53 chromatin immunoprecipitation assay and microRNA assessment that CD46 gene expression was directly and indirectly regulated by p53. Primary myeloma cells overexpressed CD46 as compared with normal cells and were highly infected and killed by MV. CD46 expression and MV infection were inhibited by nutlin3a in primary p53-competent myeloma cells, but not in p53-deficient myeloma cells, and the latter were highly sensitive to MV infection. In summary, myeloma cells were highly sensitive to MV and infection inhibition by the p53 pathway was abrogated in p53-deficient myeloma cells. These results argue for an MV-based clinical trial for patients with p53 deficiency.<br /> (© 2018 by The American Society of Hematology.)

Details

Language :
English
ISSN :
2473-9537
Volume :
2
Issue :
23
Database :
MEDLINE
Journal :
Blood advances
Publication Type :
Academic Journal
Accession number :
30530776
Full Text :
https://doi.org/10.1182/bloodadvances.2018025106